Clinical trial VISION
VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Endocyte |
| EudraCT Identifier | 2018-000459-41 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03511664 |
| Inclusion criteria | *Must have received at least one NAAD(enzalutamide or abiraterone). *1 or 2 prior treatment with taxane*Progressive disease |
| Last update |